Skip to content

Child of Urban Poverty Iron Project (CUPIP) - A Pilot Study

A Pilot Study of Micronutrient Supplementation for Child of Urban Poverty Iron Project in Selangor, Malaysia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03819530
Acronym
CUPIP
Enrollment
45
Registered
2019-01-28
Start date
2019-09-16
Completion date
2020-03-15
Last updated
2022-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron-deficiency, Iron Deficiency Anemia, Micronutrient Deficiency, Nutrient Deficiency, Stunting

Brief summary

The first 1,000 days of life are critical periods for brain development. Proper nutrition lays the foundation for optimal growth, health, and neurodevelopment across the lifespan. Poor nutrition in this vulnerable period has irreversible consequences, including stunting, susceptibility to sickness, reduced school performance and productivity, and impaired intellectual and social development. UNICEF reported in 2018 that among the low cost flat residents in urban areas of the Klang Valley, 15% of children under 5 years old were stunted, 22% underweight, and 23% either overweight or obese. Will a micronutrient supplementation program improve the growth and iron status of children aged 6 months to 5 years staying in Lembah Subang? Children will be randomized into treatment and control groups. Treatment groups will receive dietary micronutrient supplementation packets. Measurements of height and weight and iron status will be taken at baseline and 4 months later.

Detailed description

This is a pilot study in a single-centre, using a single-blind, two-parallel group, randomized trial conducted amongst children aged 6 months to 5 years residing at PPR Lembah Subang, located in the state of Selangor, Malaysia between October 2019 and February 2020 (4 months). The participants were randomly assigned in a 3:2 treatment-to-control allocation to receive, in addition to the baseline deworming treatment, either daily micronutrient packets for 4 months (intervention arm) or no micronutrient supplementation (control group). This residency area comprises a local population with mixed ethnic makeup and poor socioeconomic status (majority are B40). We distributed flyers, posters, and leaflets with the help of the community mothers in PPR communities to encourage participation. Registration, informed consent and anthropometric measurements, dietary logs and blood drawn for iron status were taken prior to randomization. All children received a baseline deworming treatment at this point. The treatment group received baseline deworming medications, a 4-month supply of daily micronutrient supplementation and a compliance monitoring log. The control group only received similar baseline deworming medications without any daily micronutrient supplementation. Only the research investigators and outcome assessors were masked to the treatment status whilst the participants and interventionists research investigators were aware of the assigned intervention. Primary endpoints assessed in this study are changes in serum ferritin and hemoglobin levels at 0 and 4 months after interventions. The secondary endpoints are changes in age-and-sex standardized height and weight percentile scores at 0 and 4 months after micronutrient supplementation.

Interventions

DIETARY_SUPPLEMENTVitamin and Mineral Powder

Vitamin and mineral nutritional supplement. Each packet is 1g of powder, to be taken with food.

Sponsors

University of Malaya
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Intervention model description

Treatment group: receives baseline deworming medication and daily micronutrient supplementation for 4 months; Control group: receives baseline deworming medication only

Eligibility

Sex/Gender
ALL
Age
6 Months to 5 Years
Healthy volunteers
No

Inclusion criteria

* Children aged 6 months to 5 years living in PPR Lembah Subang

Exclusion criteria

* Ex-premature babies and children with congenital abnormalities resulting in gross impairment * Children whose caregiver did not consent to participation

Design outcomes

Primary

MeasureTime frameDescription
Change in serum ferritin level between baseline and after 4 months mineral supplementationFirst blood test upon enrollment, at 0 months. Second blood test at 4 monthsBlood test for serum ferritin level will be done at enrollment (0 months) and again at end of study period, after 4 months of supplementation (or no supplementation for control group).
Change in reticulocyte hemoglobin level between baseline and after 4 months mineral supplementationFirst blood test upon enrollment, at 0 months. Second blood test at 4 monthsBlood test for RET-He level will be done at enrollment (0 months) and again at end of study period, after 4 months of supplementation (or no supplementation for control group).
Change in C-reactive protein level between baseline and after 4 months mineral supplementationFirst blood test upon enrollment, at 0 months. Second blood test at 4 monthsBlood test for C-reactive protein level will be done at enrollment (0 months) and again at end of study period, after 4 months of supplementation (or no supplementation for control group).

Secondary

MeasureTime frameDescription
Change in height (cm)First height measurement upon enrollment at 0 months. Second height measurement at 6 months.Height of child will be measured at baseline (0 months) and after 4 months mineral supplementation (or no supplementation for control group).
Change in weight (kg)First weight measurement upon enrollment at 0 months. Second weight measurement at 4 months.Weight of child will be measured at baseline (0 months) and after 4 months mineral supplementation (or no supplementation for control group).

Countries

Malaysia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026